@article{fdi:010081292, title = {{G}roup phenotypic composition in cancer}, author = {{C}app, {J}. {P}. and {D}e{G}regori, {J}. and {N}edelcu, {A}. {M}. and {D}ujon, {A}. {M}. and {B}outry, {J}. and {P}ujol, {P}. and {A}lix-{P}anabieres, {C}. and {H}amede, {R}. and {R}oche, {B}enjamin and {U}jvari, {B}. and {M}arusyk, {A}. and {G}atenby, {R}. and {T}homas, {F}.}, editor = {}, language = {{ENG}}, abstract = {{A}lthough individual cancer cells are generally considered the {D}arwinian units of selection in malignant populations, they frequently act as members of groups where fitness of the group cannot be reduced to the average fitness of individual group members. {A} growing body of studies reveals limitations of reductionist approaches to explaining biological and clinical observations. {F}or example, induction of angiogenesis, inhibition of the immune system, and niche engineering through environmental acidification and/or remodeling of extracellular matrix cannot be achieved by single tumor cells and require collective actions of groups of cells. {S}uccess or failure of such group activities depends on the phenotypic makeup of the individual group members. {C}onversely, these group activities affect the fitness of individual members of the group, ultimately affecting the composition of the group. {T}his phenomenon, where phenotypic makeup of individual group members impacts the fitness of both members and groups, has been captured in the term 'group phenotypic composition' ({GPC}). {W}e provide examples where considerations of {GPC} could help in understanding the evolution and clinical progression of cancers and argue that use of the {GPC} framework can facilitate new insights into cancer biology and assist with the development of new therapeutic strategies.}, keywords = {}, booktitle = {}, journal = {{E}life}, volume = {10}, numero = {}, pages = {e63518 [20 p.]}, ISSN = {2050-084{X}}, year = {2021}, DOI = {10.7554/e{L}ife.63518}, URL = {https://www.documentation.ird.fr/hor/fdi:010081292}, }